Summary & Overview
HCPCS J1555: Immune Globulin (Cuvitru) Injection, 100 mg
HCPCS Level II code J1555 denotes the administration of 100 mg of immune globulin (brand name Cuvitru). This code is important for documenting and billing subcutaneous immune globulin therapy used in immunodeficiency and certain immune-mediated conditions. Nationally, accurate capture of J1555 supports clinical continuity, payer adjudication, and appropriate reimbursement for a high-cost biologic therapy administered outside the inpatient setting. Key payers covered in this publication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for the product, common sites of service, and payer inclusion. The report outlines available benchmarks and coverage considerations where provided, highlights common modifier usage from the input, and summarizes how J1555 is described in claims workflows. Data not available in the input is clearly noted where applicable. This resource is intended to inform billing, coding, and revenue teams on the clinical coding identity of J1555, payer presence in the analysis, and where to look for policy updates related to subcutaneous immune globulin administration.
Billing Code Overview
HCPCS Level II code J1555 represents Injection, immune globulin (cuvitru), 100 mg. This code describes a parenteral immune globulin product administered as a subcutaneous infusion for patients requiring immunoglobulin replacement or immunomodulatory therapy. The service type is an injection / infusion of immune globulin. The typical site of service is outpatient infusion settings, including ambulatory infusion centers and hospital outpatient departments, as well as home infusion when clinically appropriate.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with primary immunodeficiency or secondary hypogammaglobulinemia requiring subcutaneous immune globulin replacement. The patient presents to an ambulatory infusion clinic or receives home infusion services managed by a specialty pharmacy. The clinician (allergy/immunology, hematology, or infectious disease specialist) documents indication, baseline weight, immunoglobulin G (IgG) trough levels, prior tolerance of intravenous immunoglobulin, and a dosing plan measured in mg/kg converted to vial units of J1555 (100 mg per unit). Nursing performs patient education on subcutaneous administration, prepares the calculated dose, checks for allergies and infusion-site skin integrity, and administers via subcutaneous infusion pump or manual push per manufacturer instructions. Observation for infusion reactions occurs during and for a period after administration; emergency medications and protocols are available. Documentation includes product lot number, units administered (number of J1555 units), infusion rate, site(s) used, premedications, and any adverse events. Billing uses J1555 units for product administered; appropriate modifiers are appended per payer rules for facility, professional, or circumstance-based adjustments.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |